Table 2.

Adverse events during induction and maintenance phases

	Induction phase: 1–4 cycles (N = 47)		Maintenance phase: 5 cycles- (N = 41)
	All grade	Grade ≥ 3	All grade	Grade ≥ 3
Leukopenia	46 (97.8%)	28 (59.6%)	4 (9.8%)	0
Neutropenia	46 (97.8%)	45 (95.7%)	2 (4.9%)	0
Febrile neutropenia	4 (8.5%)	4 (8.5%)	0	0
Anemia	47 (100%)	2 (4.3%)	27 (65.9%)	0
Thrombocytopenia	27 (57.4%)	0	7 (17.1%)	0
Hypoalbuminemia	43 (91.5%)	0	7 (17.1%)	0
AST increased	12 (25.5%)	0	7 (17.1%)	0
ALT increased	17 (36.2%)	1 (2.1%)	5 (12.2%)	0
ALP increased	18 (37.3%)	0	8 (19.5%)	0
Creatinine increased	25 (53.2%)	0	17 (41.5%)	0
Anorexia	43 (91.5%)	6 (12.8%)	3 (7.3%)	0
Nausea	39 (83.0%)	6 (12.8%)	4 (9.8%)	0
Vomiting	13 (27.7%)	0	0	0
Diarrhea	17 (36.2%)	3 (6.4%)	2 (4.9%)	0
Constipation	19 (40.4%)	0	2 (4.9%)	0
Weight loss	27 (57.4%)	0	8 (19.5%)	0
Fatigue	24 (51.1%)	0	6 (14.6%)	0
Alopecia	38 (80.9%)	0	19 (46.3%)	0
Oral mucositis	10 (21.3%)	0	1 (2.4%)	0
Sensory neuropathy	8 (17.0%)	0	10 (24.4%)	0
Fever	7 (14.9%)	1 (2.1%)	2 (4.9%)	0
Hypertension	44 (93.6%)	15 (31.9%)	34 (82.9%)	14 (34.1%)
Proteinuria	32 (68.1%)	0	13 (31.7%)	0
Nasal bleeding	9 (19.1%)	0	5 (12.2%)	0

Abbreviations: AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase